respectively. Primary patency and AFS at 2-years was 38% and 52%, respectively. Limb salvage at 59 one and 2-years was 70% and 65%. Fifteen (63%) patients required reintervention during the 60 follow-up period with 40% of those subjects undergoing multiple procedures.
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Average duration of follow-up was 27.9 ± 20.4 months (range 0.5 -60.4). Mean length of 56 stay was 14.8 days. Reinfection requiring an additional procedure or antibiotic regimen separate 57 from the index antibiotic course was 13%. Primary patency and AFS at 1-year was 50% and 58%, 58 respectively. Primary patency and AFS at 2-years was 38% and 52%, respectively. Limb salvage at 59 one and 2-years was 70% and 65%. Fifteen (63%) patients required reintervention during the 60 follow-up period with 40% of those subjects undergoing multiple procedures.
62
Conclusions:
63
CHs remain a marginal salvage conduit in the setting of infection and no autogenous 64 choices. Therefore, clinicians should individualize usage of this high-cost product in highly selected
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Introduction
Autogenous single-length vein continues to remain the gold standard conduit for lower 69 extremity infected-field revascularizations for critical limb ischemia (CLI). 1 However, up to 45% of 70 patients who require bypass do not have adequate continuous vein secondary to chronic venous 71 disease or previous vein harvest. 2, 3 Unfortunately, the use of alternative synthetic conduits such as infected surgical field. The purpose of this retrospective analysis was to define outcomes for 75 contemporary use of CHs in infected fields with respect to patency and limb salvage.
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Methods
78
After obtaining Indiana University Institutional Review Board (IRB) approval, a single-79 center retrospective review was completed of all infected-field CHs implanted for infrainguinal 80 arterial disease from 2012 to 2015. All procedures were performed at one institution by a group of 81 nine academic surgeons. Patients not seen by a vascular surgeon in our system for 12-months were 82 deemed lost to follow-up; for those, contact by phone was attempted.
84
Demographics captured included age, sex, disease severity, and relevant comorbidities.
85
Presence of infection was defined as observation of cellulitis overlying a bypass graft or perigraft 
91
CHs implanted were kept on-site in a liquid nitrogen dewar. These conduits were prepared 92 per manufacturer's instruction but not routinely seromatched to the host. Based on availability and 93 surgeon preference, the choice of cryopreserved vein or artery was made on a case-by-case basis.
94
CHs were used as the first choice in infected fields during this time over rifampin soaked prosthetic 
156
NSTEMI several days post-operatively. Three (13%) patients experienced anastomotic bleeding our population at one and 2-years was 50% and 38%. AFS at one and 2-years was 58% (6 M A N U S C R I P T ACCEPTED MANUSCRIPT amputations, 5 deaths) and 50% (7 amputations, 7 deaths). Limb salvage at one and 2-years was 165 70% and 65%, respectively. Reintervention rate during follow-up was 63% with 40% of these 
228
Unfortunately, the retrospective nature of this study makes it impossible to be sure all 229 adverse events were tracked and captured. As many patients were referred to us from outside 230 vascular surgeons and hospital systems -their follow-up often occurred external to our records. 
